Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095693 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00095693: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00095693 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00095693, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have locally advanced, metastatic, or locally recurrent thyroid cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- RADIATION fludeoxyglucose F 18
- PROCEDURE positron emission tomography
- DRUG sorafenib tosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095693
The ClinicalTrials.gov registry entry for NCT00095693 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00095693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095693 about?
NCT00095693 is a clinical study titled "Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer". Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have locally advanced, metastatic, or locally recurrent thyroid cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the ...
What is the current status of trial NCT00095693?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2004-10. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00095693?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), fludeoxyglucose F 18 (RADIATION), positron emission tomography (PROCEDURE), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00095693?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.